Heron Therapeutics, Inc. (HRTX)
After hours:
| Previous close | 1.8400 |
| Open | 1.8500 |
| Bid | 1.8500 x 1000 |
| Ask | 1.8800 x 500 |
| Day's range | 1.8100 - 1.8750 |
| 52-week range | 0.5000 - 3.9300 |
| Volume | |
| Avg. volume | 2,368,233 |
| Market cap | 283.619M |
| Beta (5Y monthly) | 1.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings date | 12 Nov 2024 - 18 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.75 |
Simply Wall St.Exploring Three High Growth Tech Stocks in the United States
Over the last 7 days, the market has dropped 4.4%, yet in the last year, it is up 19%, with earnings forecast to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks that align with these trends can be crucial for investors seeking robust opportunities in the United States market.
PR NewswireHeron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management
Simply Wall St.Heron Therapeutics Second Quarter 2024 Earnings: EPS Misses Expectations
Heron Therapeutics ( NASDAQ:HRTX ) Second Quarter 2024 Results Key Financial Results Revenue: US$36.0m (up 13% from 2Q...
